The Online Investor
Albireo Pharma Inc (ALBO)

Albireo Pharma is a commercial-stage biopharmaceutical company focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Co.'s product pipeline includes: Bylvay, which is approved in the U.S. and Europe for the treatment of pruritis in patients with progressive familial intrahepatic cholestasis; elobixibat, which is approved in Japan for the treatment of chronic constipation; A3907, its primary candidate for the treatment of adult liver diseases; and A2342, its primary preclinical candidate for the treatment of adult viral and liver diseases.
Company Name: 
Albireo Pharma Inc
Website: 
www.albireopharma.com
Sector: 
Drugs & Pharmaceuticals
Quotes delayed 20 minutes

Email EnvelopeFree ALBO Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Buy (2.57 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)

Analysts' Target Price:
ALBO Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Albireo Pharma Inc (ALBO) Page | The Online Investor Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2024, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.